



ASX Release Stock Code: PRR

Wednesday, 16 April 2008

Institutional Research Report Commences

Prima Biomed Ltd wishes to advise that institutional research has been commenced by Wise Owl and a copy of this report is available through the Wise Owl website (wise-owl.com) or the Prima Biomed website.

Martin Rogers

Director

Prima Biomed Ltd

Mob: +61 428 268 357

Ph: +61 2 9232 4420

Email: martin.rogers@primabiomed.com.au

About Prima Biomed Ltd

Prima Biomed (ASX: PRR) is a biotechnology company based in Sydney, Australia. The Company is focused on technologies in the fields of immunology and cancer immunotherapy. Prima is focused on developing a dendritic-cell based immunotherapy targeting mucin-1 tumour expressed antigen. Prima's lead product, CVac™ has completed Phase IIa clinical development in Ovarian Cancer and is working to a path of US FDA IND approval.

For further information, visit www.primabiomed.com.au

This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing and results of clinical trials, interpretation and implications of such results, availability or adequacy of financing, the sales and marketing of commercial products or the efficacy of products. Although the Company believes that the forward - looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward - looking statements are expressly qualified in their entirety by this cautionary statement.

Prima BioMed Ltd, Suite 1705, 109 Pitt St, Sydney NSW 2000 AUSTRALIA

www.primabiomed.com.au Ph:+61 2 9232 4420 Fax:+61 2 9232 4450

ABN: 90 009 237 889